Fall River, MA (PRWEB) April 7, 2011
NuOrtho Surgical, Inc. announced today the appointment of Gregory Rainey to its board of directors. Mr. Rainey has extensive experience in the medical device industry in various senior executive roles. Since 2004, Mr. Rainey has been the president of CCI Performance Group, LLC, which provides consulting services for healthcare companies.
NuOrtho Surgical CEO, Jeff Morrill stated: "Greg Rainey is a well respected medical device executive. Under his leadership as Vice President of Sales, the Stryker Orthopedics Division nearly doubled sales to over $1 billion dollars in just 4 years. For the last 7 years he has been helping companies similar to ours establish strong commercial success. And Greg also brings valuable board experience to NuOrtho from his director roles at RTI Biologics and CAS Medical. We believe his considerable commercial experience and his success in creating value for patients, physicians and shareholders will be extremely helpful to NuOrtho as we continue to expand the commercialization of our soft tissue platform.”
Mr. Rainey commented: "I look forward to working with a very talented management team at NuOrtho as they are launching their first product, Ceruleau, for better healthcare treatment of cartilage in the knee for the orthopedic market. It’s exciting to be joining such an innovative company that has tremendous potential for improving orthopedic outcomes for patients and physicians.”
In addition to his role as President of CCI Performance Group, Mr. Rainey is a member of the Board of Directors at RTI Biologics, Inc, as well as a Board member at CAS Medical Systems, Inc. Mr. Rainey spent the majority of his career at Stryker Corporation where his roles included Vice President of Sales and member of the Executive Committee of Stryker’s $1.2 billion orthopedic division.
About NuOrtho Surgical Inc.
NuOrtho Surgical is focused on surgical instruments to enable Tissue Preservation℠ in the orthopedic arena to improve patient outcomes. The technology leverages a low level Radio Frequency energy to restore mobility in patients by preserving healthy tissue in both soft and hard tissue procedures. NuOrtho has three primary product platforms for preserving healthy Tissue to sustain long-term mobility in our busy lives, particularly for Baby Boomers. These platforms include Soft Tissue Treatment, Agent Delivery and Bone Fusion. More information can be found at http://www.nuorthosurgical.com